Condition: Non-small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| NHO Revive Research Institute LLC ( Site 0118) | Lincoln, Nebraska, United States | Recruiting |
| New York Oncology Hematology P.C ( Site 9000) | Albany, New York, United States | Recruiting |
| Clinica Adventista Belgrano ( Site 0304) | Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303) | Mar del Plata, Buenos Aires, Argentina | Recruiting |
| Hospital Britanico de Buenos Aires ( Site 0305) | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
| Sanatorio Parque ( Site 0302) | Rosario, Santa Fe Province, Argentina | Recruiting |
| Zhongshan Hospital Affiliated to Xiamen University ( Site 2213) | Xiamen, Fujian, China | Recruiting |
| The First Affiliated Hospital of Xiamen University. ( Site 2239) | Xiamen, Fujian, China | Recruiting |
| Guangxi Medical University Affiliated Tumor Hospital ( Site 2202) | Qingxiu District, Guangxi, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206) | Wuhan, Hubei, China | Recruiting |
| Hubei Cancer Hospital ( Site 2203) | Wuhan, Hubei, China | Recruiting |
| Nanjing Drum Tower Hospital ( Site 2224) | Nanjing, Jiangsu, China | Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07554339